注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Compass Therapeutics Inc是一家临床阶段、以肿瘤学为重点的生物制药公司。该公司专注于开发基于抗体的疗法来治疗多种人类疾病。其候选产品管道针对抗肿瘤反应所需的多种关键生物途径,包括通过血管生成靶向药物调节微血管系统。其临床阶段候选产品包括CTX-009和CTX-471。CTX-009 是一种双特异性抗体,可同时靶向Delta样配体4(DLL4) 和血管内皮生长因子A(VEGF-A)。其候选单克隆抗体产品CTX-471是一种全人类IgG4单克隆抗体,是CD137的激动剂,CD137是免疫细胞上的关键共刺激受体。它的第三个项目CTX-8371是一种双特异性抗体,可与目标检查点抑制剂抗体PD-1和PD-L1结合。它还在开发一系列双特异性和单克隆抗体产品候选者。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Vered Bisker-Leib | 53 | 2020 | CEO & Director |
F. Stephen Hodi | - | 2019 | Member of Clinical Advisory Board |
James Patrick Boylan | 56 | 2022 | Independent Director |
Mary Ann Gray | 71 | 2022 | Independent Director |
Edward Chu | - | 2022 | Member of Clinical Advisory Board |
Richard Goldberg | - | 2022 | Member of Clinical Advisory Board |
Richard S. Lindahl | 60 | 2023 | Independent Director |
Philip J. Ferneau | 61 | 2015 | Independent Director |
Thomas J. Schuetz | 63 | 2014 | Co-Founder, President of Research & Development and Vice Chairman of the Board |
Howard S. Hochster | - | 2022 | Member of Clinical Advisory Board |
Daniel Douglas Von Hoff | 76 | 2022 | Member of Clinical Advisory Board |
Patricia LoRusso | - | 2022 | Member of Clinical Advisory Board |
Ellen V. Chiniara | 65 | 2022 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核